AstraZeneca (AZN) Earnings Date & Reports

Key Takeaways

• Total revenue rose 7% year over year to $16.21 billion, ahead of the roughly $16.0 billion consensus estimate.
• Core earnings per share (EPS) climbed 17% to $2.79, beating the consensus estimate of about $2.60 per share.
• Oncology led the way with 17% sales growth, powered by double-digit gains from Tagrisso, Imfinzi, Calquence, and Enhertu.
• AstraZeneca reaffirmed its full-year 2026 guidance for mid-to-high single-digit revenue growth and low double-digit Core EPS growth at constant exchange rates.
• The company launched a new restructuring program, "Reshaping for Sustainable Growth," targeting $1.5 billion in annual pre-tax savings by the end of 2029.
• For more on the stock, explore Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Discover automated insights by exploring Trending AI Robots.

Earnings Context and Why It Matters

AstraZeneca's third-quarter report matters because it tests whether the pharmaceutical giant can keep growing while managing patent expirations and pricing pressure in key markets. The company has faced recent trial setbacks and earlier media speculation about merger discussions, making a clean quarter an important signal of execution. Investors are also watching whether its diversified therapy areas — oncology, respiratory and immunology, and rare diseases — can offset declining sales of older medicines like Farxiga and Brilinta. With a pipeline of more than 180 projects and a wave of late-stage readouts expected in 2027, this quarter helps confirm whether AstraZeneca remains on track toward its long-term growth ambitions.

Reported Results

AstraZeneca reported third-quarter 2026 total revenue of $16.21 billion, up 7% from the prior year at both actual and constant exchange rates (CER). Core EPS reached $2.79, a 17% increase on an actual basis and 19% at CER, while reported EPS rose 23% to $2.02. Both top and bottom lines came in above analyst expectations, with revenue beating the consensus estimate of about $16.0 billion and Core EPS exceeding the roughly $2.60 consensus.

Profit attributable to owners of the parent climbed to $3.12 billion from $2.53 billion a year earlier. Oncology was the standout, growing 17%, while respiratory and immunology and rare disease also delivered solid gains. These advances helped offset headwinds from the loss of exclusivity on Farxiga and Brilinta and volume-based procurement in China. The company reaffirmed its fiscal 2026 outlook, expecting mid-to-high single-digit revenue growth and low double-digit Core EPS growth at CER, with a core tax rate of 18–22%.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. If you are looking to surface new ideas or validate your research workflow, the AI Screener offers a streamlined starting point.

Market Reaction and Investor Sentiment

Markets responded positively to the results, with AstraZeneca shares trading higher in London on the morning of the release. Investors appeared to welcome the earnings and revenue beat, the reaffirmed guidance, and evidence that growth in oncology and rare disease is compensating for pressures elsewhere in the portfolio. The results also helped reassure the market after a period of turbulence tied to earlier trial failures and merger speculation. Attention now turns to the company's execution of its restructuring program and the large pipeline readouts expected in 2027.

Forward Outlook and Key Factors to Monitor

AstraZeneca enters the final quarter of 2026 with its full-year guidance intact, signaling confidence that momentum can continue. The newly announced "Reshaping for Sustainable Growth" program will be a key area to watch. It is expected to involve up to $2 billion in one-time restructuring costs over three years while delivering $1.5 billion in annual pre-tax savings by the end of 2029, with resources redirected toward the pipeline and emerging technologies.

Investors should monitor how management balances those restructuring costs against margin expectations, particularly as research and development spending continues to rise with a larger number of late-stage trials. The company's oncology franchise, led by Tagrisso, Imfinzi, Calquence, and Enhertu, remains central to near-term growth, while declines in cardiovascular, renal, and metabolism products tied to patent expirations will need to be absorbed.

Looking ahead, the 2027 clinical catalyst calendar is a major focus. Management has highlighted upcoming readouts with a collective peak-year revenue potential of more than $20 billion, including the anticipated anti-cancer AVANZAR trial. The October completion of a $2 billion equity investment in Summit Therapeutics and collaborations with Daiichi Sankyo also add strategic dimensions to watch. As always, investors should track how pipeline progress, pricing dynamics in China, and foreign-exchange movements shape results in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations